anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A braking system for a patient support apparatus includes a caster wheel assembly. The caster wheel assembly includes a caster wheel and manually operable brake operable to brake the caster wheel. The caster wheel assembly further includes a manual brake activation handle or pedal for manually operating the manually operable brake to move between three positions, wherein said three positions include a braking position, an un-braked position, and a steer lock position. The braking system further includes an electrically powered actuator mechanically coupled to the manual brake activation handle or pedal and to the manually operable brake. When powered, the electrically powered actuator is operable to move the manually operable brake and to move the manual brake activation handle or pedal between two or more of the three positions to thereby manually operate the caster wheel in a braking mode, an un-braked mode, or a steer lock mode. And, when the actuator is unpowered, the manual brake activation handle or pedal is operable to be manually moved between two or more of the three positions to thereby manually operate the caster wheel in the braking mode, the un-braked mode, or the steer lock mode.
The abdomen will be entered and insufflated utilizing a 5 mm optical port. Only 5 mm ports will be utilized laterally to take down all anterior abdominal wall adhesions. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through a 11 or 12 mm port placed through the defect. Excision of hernia sac and preperitoneal fat and defect closure will be performed per current practice. The mesh will be secured in four points with 0-PDS sutures and/or tacked with a double crown of tacks per our current practice.
INTRODUCTION: The identification of risk factors for precursor lesions of colorectal cancer (CRC) holds great promise in the context of prevention. With this study, we aimed to identify patient characteristics associated with colorectal polyps (CPs) and polyp features of potential malignant progression. Furthermore, a potential association with gut microbiota in this context was investigated.
METHODS: In this single-center study, a total of 162 patients with CPs and 91 control patients were included. Multiple variables including information on lifestyle, diet, serum parameters, and gut microbiota, analyzed by 16S-rRNA gene amplicon sequencing and functional imputations (Picrust2), were related to different aspects of CPs.
RESULTS: We observed that elevated serum alkaline phosphatase (AP) levels were significantly associated with the presence of high-grade dysplastic polyps. This association was further seen for patients with CRC. Thereby, AP correlated with other parameters of liver function. We did not observe significant changes in the gut microbiota between patients with CP and their respective controls. However, a trend toward a lower alpha-diversity was seen in patients with CRC. Interestingly, AP was identified as a possible clinical effect modifier of stool sample beta diversity.
DISCUSSION: We show for the first time an increased AP in premalignant CP. Furthermore, AP showed a significant influence on the microbial composition of the intestine. Relatively elevated liver enzymes, especially AP, may contribute to the detection of precancerous dysplastic or neoplastic changes in colorectal lesions. The association between elevated AP, premalignant CP, and the microbiome merits further study.
OBJECTIVES: Scars resulting from injuries or surgical procedures often present both physical and aesthetic challenges. Recent studies have indicated promising results in improving postoperative scar outcomes through the combined use of specific laser technologies. Nevertheless, there remains a crucial need for further exploration to ascertain the optimal timing for initiating such treatments.
METHODS: In this retrospective investigation, a cohort of 47 adult patients who did not require hospitalization was analyzed. These patients were divided into two distinct groups: Group A, which received intervention beginning 2 weeks after their respective operations, and Group B, which commenced intervention 4 weeks postoperation. Each group underwent a comprehensive treatment protocol consisting of five laser sessions. Initially, patients underwent three sessions of V-beam pulsed-dye laser (PDL) therapy followed by two sessions of ablative fractional CO2 laser (AFL) therapy. Evaluation of outcomes was conducted using advanced imaging techniques such as Antera 3D imaging, in conjunction with established scar assessment tools including the Vancouver Scar Scale (VSS) and the University of North Carolina "4P" Scar Scale (UNC4P).
RESULTS: All patients successfully completed the full course of five treatment sessions, with no dropouts and no reported adverse events. Baseline cosmetic assessments of scars were equivalent across both groups. In Group A, the mean VSS scores decreased from 7.04 before treatment to 5.29 at 3 months posttreatment and further to 4.33 at 6 months posttreatment. Meanwhile, in Group B, scores decreased from 7.52 to 6.83 at 3 months and 6.17 at 6 months. There were no statistically significant differences in baseline VSS scores between the two groups (p = 0.34). At both the 3- and 6-month follow-up points, mean VSS scores were significantly lower in Group A compared to Group B (p < 0.05). Similar trends were observed in UNC4P scores. Statistically significant differences were noted across all time points (baseline, 3 months, and 6 months posttreatment) for both VSS and UNC4P scores (p < 0.05). Subset analysis revealed greater improvements in texture and depression volume at 3 months posttreatment, while improvements in depression area, depth, elevation variation, and area were more pronounced at the 6-month mark.
CONCLUSIONS: Early intervention using the combined 595-nm pulse dye laser and CO2 ablative fractional laser (AFL) 2- and 4-weeks post-surgery proves to be an effective and safe method for improving scar outcomes, particularly for facial surgical scars when treatment starts 2 weeks after surgery. However, further research is needed to refine our understanding and address potential study limitations.
This study will enroll patients that have a confirmed histology of early stage breast cancer. The patient will undergo a lumpectomy and will then receive partial breast 5 fractions stereotactic body radiation therapy at a dose of 6 gy for 5 fractions for treatment. Patients will be followed for 36 total months with specific follow-ups at 3, 6, 9, 12, 18, 24, and 36 months.
The invention concerns F-box structure protein 65 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes F-box structure protein 65.
A vaginal ring comprises a supporting ring 1 free of active agent. A layer 2, which contains an active agent such as a steroid, is applied on its outer rim, optionally in a continuous groove provided in the supporting ring. This layer, in turn, is coated with a layer 3 devoid of active ingredient. All components preferably comprise an LTV silicone elastomer. The ratio of the thickness of the layer 2, containing an active agent, to the layer 3, free of active agent, is about 5-50:1. As a result, a long-term and uniform release rate is achieved for the active agent.
PROBLEM TO BE SOLVED: To obtain a new polynucleotide for e.g. design of therapy protocol for infectious diseases, etc., consisting of a nucleic acid having the high sameness as a sequence coding for a human 7-transmembrane receptor polypeptide of a specific amino sequence. SOLUTION: This substance is an isolated polynucleotide comprising a nucleotide sequence being at least 80% identifiable with as a nucleotide sequence, along the whole length, coding for a human 7-transmembrane receptor (HACCH 94) polypeptide of the formula, or a new nucleotide complementary for the polynucleotide sequence. The polypeptide or polynucleotide is useful for e.g. design of remedy protocol for infectious diseases, etc. The polynucleotide is obtained from a cDNA library derived from mRNA in cells of human placenta by using a standard cloning and screening and expression sequence tag(EST) analysis.
PURPOSE:To provide a perfumery composition having high stability to prevent the deterioration of note of fragrance even in the presence of sweat and body- smell relating microorganisms and capable of effectively masking the sweat smell and body smell. CONSTITUTION:The perfumery composition is composed of three groups consisting of (A) a mixture of one or more perfumes selected from groups stable to sweat and human dermatic microorganism colony (e.g. an alcohol), (B) a mixture of one or more perfumes selected from groups other than the perfume mixture of the group A and having fragrance matching in the presence of sweat and human dermatic microorganism colony (e.g. an alcohol) and (C) a mixture of one or more perfumes selected from groups unstable in the presence of sweat and human dermatic microorganism colony to deteriorate the fragrance (e.g. a hydrocarbon). The sum of A and B is >=75wt.% and the total amount of the perfume mixture of the group C is <=25wt.%.
Patients in group A will receive CPT program daily for three weeks before HSCT (hospital stay for allogeneic-HCT). The program consists of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment. The total duration of each CPT session ranged from 45-60 minutes according to patient tolerance. The choice of airway clearance method that will be applied depends on two factors; patient preference and the individual response of the patient to treatment.
Two experimental steps: baseline skin conductance measurements (step 1, three minutes) and measurements of SC after social media stimulation with Line messages or calls (step 2, three minutes). With a 5-minute rest period after these two steps completed, then each participant fill out questionnaires for assessing anxiety and problematic smartphone use.
<P>PROBLEM TO BE SOLVED: To provide an application of AMPK-related phosphoenzyme 5.  <P>SOLUTION: A novel member of the human AMPK (a human homolog of sucrose-non-fermenting protein kinase) family is identified and called ARK5 (AMPK-Related Kinase 5). In a nutrient starvation state, ARK5 supports the survival of cells depending on Akt. Further, a PANC-1 cell line (P/ARK cell line) in which PANC-1 is stably transfected by ARK5 exhibits an increase of in vitro transferred activity by more than two times the human pancreas cancer cell line PANC-1. In a nude mouse, the P/ARK cell line exhibits an increase of tumor multiplication by more than 10 times at 12 weeks after transplantation and in the P/ARK cell line, the necrosis region in the transplanted tumor nest is significantly decreased compared to the parent PANC-1 cell line. Furthermore, in the P/ARK cell line transplanted nude mouse, muscle infiltration and mesenterial transference are remarkably observed.  <P>COPYRIGHT: (C)2004,JPO
Laser ablation (LA) has been evaluated for the minimally invasive thermal treatment of various cancers, but conventional unidirectional endoscopic ultrasound (EUS)-guided LA has limitations. Therefore, we developed a cylindrical laser diffuser to overcome the limitations of unidirectional EUS-guided LA. The purpose of this study was to compare the efficacies and safeties of EUS-guided LA using a novel cylindrical laser diffuser and radiofrequency ablation (RFA) in vivo in swine pancreas. EUS-guided RFA (15 W, 30 s, 450 J) and cylindrical interstitial LA (CILA) (5 W, 90 s, 450 J) were applied to normal pancreatic tissue in six anesthetized pigs (three per group). Laboratory tests were performed at baseline, immediately after ablation (day 0), and 2 days after procedures (day 2). Two days after procedures, all pigs were sacrificed, and histopathological safety and efficacy assessments were performed. Technically, EUS-guided RFA and CILA were performed successfully in all cases. No major complications, including perforation or acute pancreatitis, occurred during the experiment in either group. All animals remained in excellent condition throughout the experimental period, and laboratory tests provided no evidence of a major complication. Average necrotic volumes in the RFA and CILA groups were 424.2 mm3 and 3747.4 mm3, respectively, and average necrotic volume was significantly larger in CILA group (p < 0.001). EUS-guided RFA and CILA had acceptable safety profiles in the normal swine pancreas model. Our findings indicate EUS-guided CILA has potential for the effective local treatment of pancreatic cancer as an alternative to EUS-guided RFA.
C13 methacetin dissolved in water to be ingested after breath baseline collected. Metabolism to measured in real time.
<P>PROBLEM TO BE SOLVED: To provide methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies.  <P>SOLUTION: The methods utilize administration of microorganisms to the subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies, thereby reducing the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PRIMARY OBJECTIVES: I. To determine the safety of intradermal administration of 3 doses of a plasmid-based DNA vaccine encoding the ICD of HER2 administered with a fixed dose of GM-CSF. II. To determine whether a plasmid DNA vaccine encoding the ICD of HER2 can elicit HER2 specific immune responses. SECONDARY OBJECTIVES: I. To determine if the dose of the plasmid-based DNA vaccine effects immunologic responses. II. To determine the persistence of DNA at the site of vaccination. OUTLINE: This is a dose-escalation study of a plasmid-based DNA (pNGVL3-hICD) vaccine. Patients receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically for up to 15 years with primary physicians.
(PEG)-lipid conjugates and methods of preparation are disclosed herein. Methods of preparation may involve stepwise addition of small PEG oligomers to a glycerol backbone until a desired chain size is attained. Polymers resulting from the syntheses may be highly monodisperse. The resulting polymers may comprise branched polyethyleneglycol (PEG)-lipid conjugates. The present disclosure may provide several advantages such as simplified synthesis, high product yield and low cost for starting materials. The present synthesis method may be suitable for preparing a wide range of conjugates such as PEG lipid conjugates having a glycerol-like central backbone covalently attached to two or more monodisperse PEG chains and a lipid comprising a range of diesters made from fatty acids or bile acids.
The investigators are proposing to carry out a clinical trial. Around 100 stable hemodialysis adult patients at Makassed general hospital dialysis center and around 150 patients at Sahel general hospital and Zahraa hospital will be assessed according to the international RLS criteria. The data on individual, clinical and laboratory indices will be obtained from patients' recorded files and interviews. The investigators will compare the RLS group versus the non RLS group according to these factors to find the independently associated factors for RLS in dialysis patients.

Those who fulfill all four diagnostic criteria for RLS (confirmed independently by 2 neurologists) will be classified as "RLS positive" and will be asked to answer 10 questions on the international RLS study group (IRLSSG) rating scale. The IRLSSG rating scale was also used to evaluate the severity of RLS symptoms. These patients will be randomly allocated to two parallel groups to receive vitamin C (200 mg) or placebo for eight weeks.
The recommended starting dose of testosterone gel 1% is 50 mg of testosterone (4 pump actuations, two 25 mg packets, or one 50 mg packet), applied topically once daily in the morning to the shoulders and upper arms and/or abdomen area (preferably at the same time every day). 

Dose Adjustment   
To ensure proper dosing, serum testosterone concentrations should be measured at intervals. If the serum testosterone concentration is below the normal range, the daily testosterone gel 1% dose may be increased from 50 mg to 75 mg and from 75 mg to 100 mg for adult males as instructed by the physician (see Table 1, Dosing Information for testosterone gel 1%). If the serum testosterone concentration exceeds the normal range, the daily testosterone gel 1% dose may be decreased. If the serum testosterone concentration consistently exceeds the normal range at a daily dose of 50 mg, testosterone gel 1% therapy should be discontinued. In addition, serum testosterone concentrations should be assessed periodically. 

The application site and dose of testosterone gel 1% are not interchangeable with other topical testosterone products.
PURPOSE: To establish a prediction model for repeated shockwave lithotripsy (SWL) efficacy to help choose an appropriate treatment plan for patients with a single failed lithotripsy, reducing their treatment burden.
PATIENTS AND METHODS: The clinical records and imaging data of 304 patients who underwent repeat SWL for upper urinary tract calculi (UUTC) at the Urology Centre of Shiyan People's Hospital between April 2019 and April 2023 were retrospectively collected. This dataset was divided into training (N = 217; 146 males [67.3%] and 71 females [32.7%]) and validation (N = 87; 66 males [75.9%] and 21 females [24.1%]) sets. The overall predictive accuracy of the models was calculated separately for the training and validation. Receiver operating characteristic (ROC) curves were plotted, and the area under the ROC curve (AUC) was calculated. The normalized importance of each independent variable (derived from the one-way analyses) in the input layer of the artificial neural network (ANN) model for the dependent variable (success or failure in repeat SWL) in the output layer was plotted as a bar chart.
RESULTS: This study included 304 patients, of whom 154 (50.7%) underwent successful repeat SWL. Predictive models were constructed in the training set and assessed in the validation set. Fourteen influencing factors were selected as input variables to build an ANN model: age, alcohol, body mass index, sex, hydronephrosis, hematuria, mean stone density (MSD), skin-to-stone distance (SSD), stone heterogeneity index (SHI), stone volume (SV), stone retention time, smoking, stone location, and urinary irritation symptom. The model's AUC was 0.852 (95% confidence interval (CI): 0.8-0.9), and its predictive accuracy for stone clearance in the validation group was 83.3%. The order of importance of the independent variables was MSD > SV > SSD > stone retention time > SHI.
CONCLUSION: Establishing an ANN model for repeated SWL of UUTC is crucial for optimizing patient care. This model will be pivotal in providing accurate treatment plans for patients with an initial unsuccessful SWL treatment. Moreover, it can significantly enhance the success rate of subsequent SWL treatments, ultimately alleviating patients' treatment burden.
A topical composition, comprising: an inflammatory management agent comprising lactose and/or milk protein, the inflammatory management agent being present in an amount of from about 0.01 wt. % to about 12.5 wt. % based on the weight of the topical composition; a vascular repair agent comprising palmitoyl glycine, the vascular repair agent being present in an amount of from about 0.01 wt. % to about 15 wt. % based on the weight of the topical composition; a neurogenic agent comprising an oligosaccharide, the neurogenic agent being present in an amount of from about 0.01 wt. % to about 22.5 wt. % based on the weight of the topical composition; a sebum suppression agent comprising Panthenyl Triacetate, farnesol and farnesyl acetate, the sebum suppression agent being present in an amount of from about 0.01 wt. % to about 25 wt. % based on the weight of the topical composition; and an exfoliating agent comprising at least one plant derived cysteine protease enzyme, the exfoliating agent being present in an amount of from about 0.01 wt. % to about 10 wt. % based on the weight of the topical composition.
As described herein, a system includes an optical sensor, and a controller that detects progression of obstructive coronary artery disease using a sensor signal from the optical sensor. For example, the system is used for detecting an occlusion in a cardiovascular system of a user. A computer-implemented method for detecting the occlusion includes generating a light within a predetermined spectral range, the light directed towards a reflective element at a predetermined angle. The method further includes receiving a reflected light caused by a reflection of the light off of a reflecting element that is in contact with the user's epidermis. The method further includes detecting a concentration of a predetermined biomarker in a biofluid in the cardiovascular system based on variations in amplitude of the reflected light. The method further includes determining an occlusion in the cardiovascular system based on the concentration of the predetermined biomarker.
The hepatitis B virus (HBV) capsid or core protein is a promising drug target currently being investigated for potential curative therapies for chronic HBV infection. In this study, we performed extensive in vitro and in vivo characterization of a novel and potent HBV core protein assembly modulator (CpAM), CU15, for both anti-HBV activity and druggability properties. CU15 potently inhibited HBV DNA replication in in vitro HBV-infected HepG2.2.15 cells (EC50 of 8.6 nM), with a low serum shift. It was also effective in inhibiting HBV DNA and cccDNA formation in de novo HBV-infected primary human hepatocytes. Furthermore, CU15 was active across several HBV genotypes and across clinically relevant core protein variants. After oral administration to an in vivo HBV mouse model, CU15 significantly reduced plasma HBV DNA and RNA levels, at plasma exposure consistent with the estimated in vitro potency. In vitro, CU15 exhibited excellent passive permeability and relatively high metabolic stability in liver preparations across species (human > dog> rat). In vitro human liver microsomal studies suggest that the compound's major metabolic pathway is CYP3A-mediated oxidation. Consistent with the in vitro findings, CU15 is a compound with a low-to-moderate clearance and high oral bioavailability in rats and dogs. Based on the apparent in vitro-in vivo correlation observed, CU15 has the potential to exhibit low clearance and high oral bioavailability in humans. In addition, CU15 also showed low drug-drug interaction liability with an acceptable in vitro safety profile (IC50 > 10 µM).